Reig Jofre launches sleep supplement in France
Forté Pharma's new nutritional supplement combines natural extracts: valerian, passionflower, and vitamins B3 and B6, which contribute to prolong sleep for 8 hours.
Forté Pharma, Reig Jofre’s nutritional supplements line, has launched Forté Nuit 8h in France, its home market. The new nutritional supplement extends the company's health range and represents the natural alternative to help to fight sleep disorders.
Forté Nuit 8h improves the latency time; it also provides quality rest for 8 hours, without drowsiness or side effects upon awakening and without causing dependence.
Forté Nuit 8h acts with a double effect thanks to its natural formula, the optimal dose of its ingredients and its original bilayer tablets format, which provides an immediate effect through the rapid melatonin release that favors the first phase of the sleep cycle, as well as a long-acting effect thanks to the combination of natural extracts, valerian, passionflower, and vitamins B3 and B6, which contribute to prolong sleep for 8 hours.
Forté Pharma is planning Forté Nuit 8h’s international expansion and will start its marketing in Belgium during the first quarter of 2018.
Regarding the Spanish market, Forté Pharma plans to continue the development of the weight control segment during the first half of the year and to boost the rest of the categories in the second half.
Forte Pharma's portfolio is organized into four segments: energy (35% of its total sales), slimming (30%), health (22%) and beauty (13%) as at the end of September 2017.
At present, the marketing of Forte Pharma products is conducted mostly in Europe through its own sales network. Forte Pharma’s home market - France - is still the first market of the brand, which accounted for 67% of sales.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.